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Background: Gastrointestinal stromal tumors are sarcomas of the digestive tract characterized by mutations mainly
located in the c-KIT or in the platelet-derived growth factor receptor (PDGFR)-alpha genes. Mutations in the BRAF
gene have also been described. Our purpose is to define the distribution of c-KIT, PDGFR and BRAF mutations in a
population-based cohort of gastrointestinal stromal tumors (GIST) patients and correlate them with anatomical site,
risk classification and survival. In addition, as most of the GIST patients have a long survival, second cancers are
frequently diagnosed in them. We performed a second primary cancer risk assessment.
Methods: Our analysis was based on data from Tarragona and Girona Cancer Registries. We identified all GIST
diagnosed from 1996 to 2006 and performed a mutational analysis of those in which paraffin-embedded tissue was
obtained. Observed (OS) and relative survival (RS) were calculated according to risk classifications and mutational
status. Multivariate analysis of variables for observed survival and was also done.
Results: A total of 132 GIST cases were found and we analyzed mutations in 108 cases. We obtained 53.7% of
mutations in exon 11 and 7.4% in exon 9 of c-KIT gene; 12% in exon 18 and 1.9% in exon 12 of PDGFR gene and
25% of cases were wild type GIST. Patients with mutations in exon 11 of the c-KIT gene had a 5-year OS and RS of
59.6% and 66.3%, respectively. Patients with mutations in exon 18 of the PDGFR gene had a 5-year OS and RS of
84.6% and 89.7%. In multivariate analysis, only age and risk group achieved statistical significance for observed
survival. GIST patients had an increased risk of second cancer with a hazard ratio of 2.47.
Conclusions: This population-based study shows a spectrum of mutations in the c-KIT and PDGFR genes in GIST
patients similar to that previously published. The OS and RS of GIST with the exon 18 PDGFR gene mutation could
indicate that this subgroup of patients may be less aggressive and have a good prognosis, although less sensitive
to treatment at recurrence. In our study, GIST patients have an increased risk of developing a second neoplasm.
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Gastrointestinal stromal tumors (GIST) are the most
common sarcomas of the digestive tract, with an inci-
dence of 1.1 to 1.4 cases/100,000 inhabitants/year [1-3].
It was initially described by Mazur and Clark [4] in 1983
and develops from the interstitial cells of Cajal in the di-
gestive tract. In 1998, Hirota and colleagues [5] identified a
gain-of-function mutation in the c-KIT gene that character-
ized this tumor. Mutations in the c-KIT gene led to consti-
tutive activation of a tyrosine kinase receptor that induced
oncogenesis [6]. In some GIST in which mutations in c-
KIT have not been identified, oncogenic mutations have
been reported in the gene encoding the platelet-derived
growth factor receptor-alpha (PDGFR-α) [7].
Mutations in the c-KIT and PDGFR-α genes are clus-
tered in just a few exons. The type of mutation has been
correlated with prognosis, localization of primary tumors,
initial sensitivity and later resistance to imatinib treatment
and association with hereditary syndromes [8,9].
BRAF gene mutations had initially been described in
13% of wild-type GIST [10], although recently they have
also been reported in 2% of GIST carrying activating KIT
and PDGFR-α mutations and conferring a worse progno-
sis and resistance to imatinib treatment [11]. Some other
mutations in oncogenes such as PTEN, KRAS and
NTRK2 have been described, especially in wild-type KIT
GIST [12].
In 2001, the characteristics of GIST and the diagnostic
approach were established by expert consensus [13].
Since this meeting, a positivity in c-KIT immunohisto-
chemistry test has been mandatory for diagnosis of
GIST, although some cases, about 5%, may be c-KIT
negative. Also, GIST patients were classified into differ-
ent groups regarding risk of malignant behavior accord-
ing to tumor size and number of mitoses, with different
survival for each [1].
The introduction of imatinib mesilate in 2002 pro-
duced a remarkable change in the results of therapy with
GIST patients [14].
Focusing on the epidemiology of this type of neo-
plasm, our purpose is to define the distribution of KIT,
PDGFR-alpha and BRAF mutations in a population-
based cohort of GIST and correlate them with risk clas-
sifications and survival.
GIST patients are frequently diagnosed of a second can-
cer probably due to the long survival of the less aggressive
tumors. In addition, gastric GIST has been described as
Carney triad disease including also extra-adrenal paragan-
glioma and pulmonary chondroma and an association be-
tween GIST and type 1 neurofibromatosis has also been
established. Those inherited GIST are in most cases not
related to c-KIT or PDGFRA mutations [15,16]. We also
present our results in a population-based evaluation of
risk of secondary malignances after GIST.Methods
Our analysis was based on data from two cancer registries
in the North-East of Spain. The Girona Cancer Registry
(GCR) is a population-based cancer registry covering the
province of Girona, which began its activity in 1994. In
this area we analyzed the time period 1996 to 2006. The
Tarragona Cancer Registry (TCR) is a population-based
cancer registry that has registered all malignant tumors in
the province of Tarragona since 1980. In this area we ana-
lyzed the time period 1998 to 2006. These cancer registries
record cancers according to International Agency for
Research on Cancer (IARC) guidelines [17].
We decided to analyze both areas together because
they are geographically close and their population has
very similar demographic characteristics. According to
census data from the Catalan Institute of Statistics
(available at URL: www.idescat.cat), in 2006 Tarragona
had 729,671 inhabitants (50.6% male) and the age distri-
bution was 14.3% in the range 0 to 14 years old, 68.0%
in the range 15 to 64 years-old and 17.8% over 64 years
old. At the same time, Girona had 681,387 inhabitants
(50.5% male) and the age distribution was 14.4% in the
range 0 to 14 years old; 67.7% in the range 15 to 64 years
old and 17.9% over 64 years old.
As some of low-risk GIST tumors had been considered
benign in the past and could have been missed by Can-
cer Registries [2], we additionally requested that the
pathology departments of both areas reviewed all cases
of sarcoma of the intestinal tract and reclassified them
performing immunohistochemistry using CD117, CD34
and other markers such as desmin, S-100 protein and
smooth muscle actin to correctly diagnose GIST.
Clinical data of patients was obtained and GIST were
classified by risk group of malignant behavior as defined in
the National Institutes of Health GIST workshop in April
2001 and published by Fletcher et al. [13] in 2002, which
was the classification system widely used in the years cov-
ered by our analysis. We also show data using the Armed
Forces Institute of Pathology (AFIP) classification defined
by Miettinen et al. [18], for which we reclassified all cases.
We asked for paraffin-embedded tissue samples of all
cases and searched mutations in exons 9, 11, 13 and 17
in the KIT gene and exons 12 and 18 in the PDGFR-α
gene. In wild-type cases for both genes, we searched for
BRAF gene mutations.
Formalin-fixed, paraffin-embedded tumor blocks were
reviewed by expert pathologists for quality and tumor
content and a single representative tumor block from each
patient, containing at least 80% of neoplastic cells, was se-
lected. Genomic DNA was extracted using the QIAamp
DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) as spe-
cified by the manufacturer’s instructions.
KIT mutations in exons 9, 11, 13 and 17, PDGFRα
mutations in exons 12 and 18 and BRAF mutations in
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lysis was performed by polymerase chain reaction (PCR)
amplification and subsequent sequencing analysis. Muta-
tional analysis was performed using previously reported
PCR conditions and primers (Table 1) for exons 9, 11, 13
and 17 of the KIT gene [19,20], for exons 12 and 18 of the
PDGFRα gene [21,22] and for exon 15 of the BRAF gene
[10]. Each sample was capillary-electrophoresed on an
ABI PRISM 310 Genetic Analyzer (Applied Biosystems,
Foster City, USA).
Follow-up time was calculated as the time between the
date of diagnosis and the date of death, if the patient
was dead, or data from the last check-up if the patient
was alive. We also obtained patients’ vital status by
means of record linkage to the Mortality Registry of
Catalonia and the Spanish National Death Index, up-
dated until 31 December 2012.
Relative survival (RS) was defined as the ratio between
observed survival (OS) and expected survival and was cal-
culated to express the probability of cancer patients surviv-
ing after adjustment for competing causes of death [23].
Survival was estimated using only first tumors. RS rates
were calculated using the Hakulinen method [24]. Expected
survival was estimated using mortality tables for Catalonia.
The chi-square test was used to determine whether
the type of mutation was related to the tumor site,
Fletcher risk group and AFIP risk group.
Using Cox regression models, age, sex, type of muta-
tion, risk group according to Fletcher’s or AFIP’s classifi-
cation and localization were investigated as potential
prognostic factors for impact on observed survival in
multivariate analyses. The same variables were analyzed
in univariate model using log-Rank test.Table 1 Primer sequences used for PCR
Location Primer sequence Size
(in bp)
c-KIT exon 9 F: 5′-TCCTAGAGTAAGCCAGGGCTT-3′ 283
R: 5′-TGGTAGACAGAGCCTAAACATCC-3′
c-KIT exon 11 F: 5′-CCAGAGTGCTCTAATGACTG-3′ 215
R: 5′-AGCCCCTGTTTCATACTGAC-3′
c-KIT exon 13 F: 5′-GCTTGACATCAGTTTGCCAG-3′ 193
R: 5′-AAAGGCAGCTTGGACACGGCTTTA-3′
c-KIT exon 17 F: 5′-GGTTTTCTTTTCTCCTCCAACC-3′ 203
R: 5′-GATTTACATTATGAAAGTCACAGG-3′
PDGFRA exon 12 F: 5′-CCAGTTACCTGTCCTGGTCAT-3′ 183
R: 5′-GGAGGTTACCCCATGGAACT-3′
PDGFRA exon 18 F: 5′-TACAGATGGCTTGATCCTGAGT-3′ 212
R: 5′-AGTGAAGGAGGATGAGCCTG-3′
BRAF exon 15 F: 5′AAACTCTTCATAATGCTTGCTCTG 3′ 200
R: 5′GGCCAAAAA TTTAATCAGTGG A 3′
bp, base pair.In terms of evaluating the risk of developing a second
cancer after a diagnosis of GIST, we performed a retro-
spective analysis in both cohorts. The IARC-IACR rec-
ommendations for the definition of multiple primaries
were used as criteria for inclusion or exclusion of tumors
as second primary cancers [25].
The standardized incidence ratio (SIR) was calculated as
the ratio between the observed number of second cancers
and the number that would be expected if patients in the
cohort experienced the same cancer incidence rates as the
general reference population. The observed number of
cases included all second cancers diagnosed in the cohort
patients, excluding non-melanoma skin cancers. If the sec-
ond cancer was a non-melanoma skin cancer, the third
cancer was considered as the ‘second’. Multiple cancers di-
agnosed before GIST were excluded. The expected num-
ber of cases was computed multiplying the cumulated
person-years observed by the incidence rates by cancer
site, 5-year age group and calendar-year of the general
population of Tarragona and Girona. Person-years ob-
served (PYO) at risk were defined as the period going
from the first cancer diagnosis to the first date among the
following: the date of second cancer diagnosis, the date of
death or the date of last known vital status (31 December
2012). The assumption that the observed number of sub-
sequent cancers followed a Poisson distribution was used
to calculate 95% confidence intervals.
All the analysis was computed using R software.
This study was approved by the Ethic Committee of
each referral Hospital of the whole area (Hospital Sant
Joan in Reus, Hospital Joan XXIII in Tarragona and
Hospital Josep Trueta in Girona).
Results
We identified 75 GIST incident cases in the Girona
Cancer Registry for the period 1996 to 2006. The crude
rate of incidence in this area and period was 1.17 cases/
100,000 inhabitants/year (World age-standardized rate of
0.68 cases and European age-standardized rate of 0.93).
In the Tarragona Cancer Registry, 57 GIST incident
cases were identified for the period 1998 to 2006, corre-
sponding to a crude rate of incidence of 1.01 cases/
100,000 inhabitants/year (World age-standardized rate
of 0.62 and European age-standardized rate of 0.85).Cohort characteristics
A total of 132 GIST cases were found for the two popula-
tions. Of these, 67 were in men (55.8%) and 53 in women
(44.2%). Median age at diagnosis was 64.5 years old.
Seventy-six cases (57.6%) were localized in the stom-
ach, 47 (35.5%) in the small intestine, 6 (4.5%) in the
peritoneum, two in the rectum (1.5%) and one in the
esophagus (0.8%).
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risk of malignant behavior according to the classification
proposed by Fletcher et al. [13], 28 cases (21.2%) were of
intermediate risk, 46 cases (34.8%) were of high risk, 14
cases (10.7%) were diagnosed with metastatic disease
and in 4 cases (3%) we did not have enough information
to classify.
Twenty-three of the 132 patients of the cohort (17.4%)
had been treated with imatinib at the end of study
follow-up. In six patients, treatment was initiated upon
diagnosis of metastatic disease. In seventeen patients, it
was initiated at recurrence following initial surgery. Of
these, 14 were initially classified as high risk of malig-
nant behavior GIST, one as intermediate risk and two as
low risk. Any patient was treated in adjuvant setting. As
some of the patients died before the widespread use of
imatinib in GIST, the impact of treatment on survival
could not be evaluated in our series.
The median follow up time was 97 months (8.09 years).
Mutational analysis
In GCR, we obtained paraffin-embedded tissue of 65
cases, corresponding to 86.6% of the total incidence. All
tissues corresponded to the primary tumor and were ob-
tained at the time of diagnosis or first surgical treatment.
In two paraffin-embedded tissues, there was insufficient
DNA to perform the mutational analysis.
In TCR, 47 paraffin-embedded tissue samples were ob-
tained (82.5% of total incident cases) and again two of
the samples did not contain sufficient DNA to perform
mutational analysis.
Finally, mutational analysis was performed in 108
paraffin-embedded tissue samples, 81.8% of the cohort.
We sequenced 297 loci from 3 cancer-related genes (KIT,
PDGFR and BRAF only in wild type GIST). All cases wereTable 2 Distribution of c-KIT and PDGFR-α genes mutations (N
c-KIT exon 11 c-KIT exon 9 PDG
N % N % N
Site (ICD-O-3 code)
Stomach (C16) 31 53.5 2 25 1
Small intestine (C17) 23 39.6 6 75 0
Colon (C18) 0 0 0
Rectum (C20) 1 1.7 0 0
Peritoneum (C48.2) 3 5.2 0 1
Fletcher’s risk groups
LR 9 15.5 2 25 0
IR 13 22.4 4 50 1
HR 33 6.9 2 25 1
Met 3 5.2 0 0
Using International Classification of Diseases for Oncology third version (ICD-O-3) and a
IR, intermediate risk; HR, high risk; Met, diagnosed in metastatic disease.c-KIT positive in immunohistochemistry except two,
which were c-KIT negative but CD-34 positive.
Table 2 shows the distribution of mutations according
to tumor site, using the International Classification of
Diseases for Oncology, third version (ICD-O-3) [26]. We
found GIST located in the stomach (C-16), small intestine
(C17), colon (C18), rectum (C19) and peritoneum (C48.1).
No GIST was found in the esophagus. Tumors registered
with C48.0 or C48.2 (retroperitoneum and peritoneum) or
C76 (abdomen not otherwise specified) were reviewed and
reclassified according to a more specific site. The distribu-
tion of mutations according to the risk groups defined by
Fletcher et al. [13] is also shown in Table 2.
Fifty-eight GIST had exon 11 c-kit mutation, corre-
sponding to 53.7% of the analyzed cases. Of these, 30
cases (51.7%) were GIST localized in the stomach, 24
(41.4) in the small intestine, 3 (5.2%) in the peritoneum
without more specific localization and one (1.7%) in the
rectum. The most frequent codons involved in exon 11
c-KIT gene mutations were 557 in 12 cases (20.7%), 558
in 14 cases (24.1%), 559 in 11 cases (18.9%) and 560 in 7
cases (12.1%). Mutations involving both codons 557 and
558 were identified in 9 cases, all diagnosed with a high-
risk or metastatic GIST and all except one case had re-
curred at the last follow-up. Table 3 describes the type
of mutation for each c-KIT and PDGFR-α exon.
We obtained eight mutations of c-KIT exon 9 (7.4%),
two of them (25%) localized in the stomach and six (75%)
in the small intestine. All of them were an insertion type
mutation Y503_F504insAY.
Thirteen GIST with mutation in exon 18 of the PDGFR-
α gene were identified, corresponding to the 12.1% of the
samples analyzed. All were located in the stomach and
most of them (53.8%) classified as low-risk GIST. Twelve
cases had mutations affecting codon 842 (11 cases D842V= 108)
FR-alpha exon 12 PDGFR-alpha exon 18 Wild type
% N % N %
50 13 100 15 55.5
0 11 40.7
0 1 3.8
0 0
50 0 0
8 61.5 14 51.9
50 4 30.8 7 25.9
50 1 7.7 5 18.5
0 1 3.7
ccording to Fletcher et al. groups of risk. LR, low risk (includes very low risk);
Table 3 Type of mutation in the 108 GIST cases analyzed
Exon mutated Type of mutation Number of cases
Exon 11 gene c-KIT V559D 8
W557_K558del 7
V560D 4
L576P 3
R558_L589insDHKWEFPRN 2
Y570_P577del 2
H580_K581insIDPTQLPY 2
V559A 2
V555_V559del 2
V560_E561del 2
T574_P577del 2
V557_K561del 1
W557_E561del 1
W557_E562del 1
T574_Q575insDP 1
V559G 1
Q556_V559 > H 1
Q556_T574del 1
P585S 1
P577S 1
N567_Q575del 1
N567_P577 > Y 1
N566Y 1
V560del 1
K558R 1
K558_V560del 1
K558_G565del 1
K550_P551insK 1
W557_V559del 1
E554_K558del 1
D579del 1
557-558 del 1
I563_P577del 1
Exon 9 gene c-KIT Y503_F504insAY 8
Exon 18 gene PDGFR-α D842V 11
D842_H845del 1
I843_D846del 1
Exon 12 gene PDGFR-α D591Y 1
W559_V561del 1
Wild type 27
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letion) and one was a I843_D846 deletion, which also cor-
responded to the only aggressive case in patients carrying
this type of mutation.Two cases had mutations of gene PDGFR-alpha exon 12
(1.9%). Twenty-seven cases (25.0%) were wild-type, of those
16 cases (59.3%) were localized in the stomach, 10 (37%) in
the small intestine and 1 (3.7%) in the peritoneum.
No BRAF mutations (searched for only in wild type
cases), nor any mutations of exon 13 or 17 of the c-KIT
gene were found.
Only 4 of those 108 GIST patients for which muta-
tional analysis was performed were diagnosed initially
with metastatic disease, 3 of them with mutation in exon
11 of c-KIT gene and 1 wild type GIST. So, GIST with
localized disease had in a 60.6% of cases mutations of
gene c-KIT (63 patients), 14.4% of cases mutations of
gene PDGFR-alpha (15 patients) and 25% (26 cases) of
wild type tumors.
We found a significant correlation between mutation
type and distribution of patients in risk groups (chi-
square test p value of 0.03), due to the predominance of
high-risk tumors in GIST with the exon 11 c-KIT muta-
tion and the predominance of low-risk GIST in the exon
18 PDGFR-α mutation. We also found differences be-
tween mutation type and GIST location (chi-square test
p value 0.008), as the majority of GIST with mutations
in the exon 18 PDGFR-α gene were in the stomach.
Survival analysis
For the whole cohort (132 cases), 10-year OS and RS
were 52.8% (N at risk 41; 95% confidence interval (CI):
44.6 to 62.5) and 66.0% (95% CI: 55.8 to 78.0), respect-
ively. Table 4 shows 5- and 10-year survival by risk
groups defined by Fletcher et al. [13] and the AFIP [18]
classifications. In four cases, we did not find sufficient
information to classify. Table 5 shows survival according
to mutational status.
One of our aims was to correlate survival according to
the risk groups defined by Fletcher et al. [13] and muta-
tional status. The small numbers of cases made this im-
possible for all mutation types except the exon 11 c-KIT
gene (Table 6) and exon 18 PDGFR-α gene.
Patients with mutations in exon 11 of the c-KIT gene
had a 5-year OS and RS of 59.6% and 66.3%, respectively.
Patients with mutation in exon 18 PDGFR-α gene had
an 85.7% 5-year observed survival (N at risk = 7; 95% CI:
63.3 to 100.0) and 89.5% 5-year relative survival (95% CI:
66.1 to 104.4) for low and very low-risk groups and 100%
5-year OS and RS (N at risk = 4) for the intermediate
group. Only one patient diagnosed with a GIST with mu-
tation in this exon was classified in the high-risk group
and progressed and died within 3 years of diagnosis.
Table 7 shows the results of the multivariate analysis for
observed survival in which age under 65 years old and low
risk tumors compared with metastatic tumors were the
two variables that achieved statistical significance. The
comparison between high- and low-risk tumors achieves
Table 4 Five- and 10-year observed and relative survival of GIST according to risk of malignant behavior classifications
Time (years) N at risk OS (95% confidence interval) RS (95% confidence interval)
All cases (N = 132)
5 84 62.9 (55.2 to 71.7) 69.7 (61.1 to 79.5)
10 41 52.8 (44.6 to 62.5) 66.0 (55.8 to 78.0)
Fletcher et al. classification
LR 5 34 82.5 (71.5 to 95.2) 88.1 (76.4 to 101.6)
10 19 73.6 (60.7 to 89.3) 88.4 (72.9 to 107.2)
IR 5 22 75.0 (60.6 to 92.9) 89.1 (70.2 to 113.1)
10 12 71.1 (56.0 to 90.2) 81.8 (66.1 to 101.3)
HR 5 28 56.2 (42.8 to 72.2) 63.0 (49.1 to 80.9)
10 11 39.1 (26.9 to 57.0) 49.0 (33.6 to 71.3)
Met 5 2 8.3 (1.3 to 54.4) 9.0 (1.4 to 58.6)
AFIP classification
LR 5 46 83.3 (74.0 to 93.9) 91.5 (81.2 to 103.1)
10 26 74.4 (63.2 to 87.6) 90.7 (77.1 to 106.8)
IR 5 14 61.9 (44.3 to 86.6) 69.2 (49.5 to 96.8)
10 7 55.0 (36.6 to 82.7) 70.5 (46.9 to 106.0)
HR 5 24 56.1 (42.8 to 73.5) 62.1 (47.3 to 81.4)
10 9 38.2 (24.9 to 58.6) 46.1 (30.1 to 70.7)
Met 5 2 8.3 (1.3 to 54.4) 9.0 (1.4 to 58.6)
LR, low risk (includes very low risk); IR, intermediate risk; HR, high risk; Met, diagnosed in metastatic disease.
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patients with a second neoplasm (HR = 4.53; 95% CI 1.60
to 12.8; p value <0.001). Results did not change when
AFIP’s classification was used instead of Fletcher’s classifi-
cation. In univariate analysis, age and risk classification
achieved statistical significance and sex, site and type of
mutation did not.
Second cancer risk assessment
Thirty patients, 22.73% of the total cohort, had a diagno-
sis of another neoplasm. Of those, eight patients had thisTable 5 Five- and 10-year observed and relative survival
of GIST
Type of
mutation
Time
(years)
N at
risk
OS (95%
confidence
interval)
RS (95%
confidence
interval)
c-KIT exon 11 5 35 59.6 (48.2 to 73.8) 66.3 (53.6 to 82.1)
10 15 50.6 (38.5 to 66.5) 65.7 (50.0 to 82.1)
c-KIT exon 9 5 8 87.5 (67.3 to 100.0) 87.5 (67.3 to 100.0)
10 4 60.0 (33.1 to 100.0) 65.3 (36.1 to 108.8)
PDGFR-α
exon 18
5 12 84.6 (67.1 to 100.0) 89.7 (71.1 to 106.0)
10 7 84.6 (67.1 to 100.0) 108.8 (86.3 to 128.6)
Wild type 5 22 75.0 (60.6 to 92.9) 83.6 (67.5 to 103.5)
10 14 67.0 (51.3 to 87.4) 79.9 (61.3 to 104.3)
According to type of c-KIT or PDGFR-α gene mutation (N = 108).neoplasm before GIST and were discarded for the final
risk analysis.
Twenty-two tumors were evaluable for second cancer
risk. Eleven were synchronic tumors (three colon cancers,
two rectal cancers, two lung cancers and one gastric,
breast, prostate and endometrium cancer, respectively).
Eleven cases were metachronic cancers (two breast and
urinary bladder cancers and one lung, esophagus, prostate,
colon, biliary tree and pancreatic cancer).
Men with GIST had an increased risk of second cancer
with SIR of 2.17 (CI 95% 1.15 to 3.71) and also was in
women with SIR of 3.08 (95% CI 1.40 to 5.88). For both
sexes together, SIR was of 2.47 (95% CI 1.54 to 3.374).
Of those 22 patients, 14 died due to cancer, but only 2
of them due to GIST.
Discussion
Our population-based study analyzes the distribution of
mutational status and survival across the whole spectrum
of GIST.
We found a predominance of c-KIT mutations of exon
11(53.7%) and 7.4% of mutations of exon 9, which corre-
lates with data from other population-based studies pub-
lished in Norway [27], Italy [28], Switzerland [29], Slovakia
[30] and France [31]. By contrast, however, in our series,
there is a high percentage (25%) of wild-type tumors
which do not normally exceed 10% to 15%. This may be
due to the use of old samples of paraffin-embedded tissue,
Table 6 Five- and 10-year observed and relative survival of GIST with exon 11 mutation
Fletcher group Time (years) N at risk OS (95% confidence interval) RS (95% confidence interval)
Low and very low 5 7 66.7 (42.0 to 100.0) 73.3 (46.2 to 109.9)
10 4 66.7 (42.0 to 100.0) 84.3 (53.1 to 126.5)
Intermediate 5 11 76.9 (57.1 to 100.0) 82.8 (61.5 to 107.7)
10 6 76.9 (57.1 to 100.0) 96.5 (71.7 to 125.5)
High 5 19 56.2 (41.4 to 76.4) 62.2 (45.8 to 84.5)
10 7 40.0 (24.8 to 64.6) 49.2 (30.5 to 79.5)
(N = 58) According to risk of malignant behavior of Fletcher et al. classification.
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tissue fixation defects or degradation of the DNA (21 of
the 27 wild-type cases were diagnosed prior to 2003).
One important finding is the distribution of tumors with
mutation of exon 18 in the PDGFR-α gene according to
the risk groups defined by Fletcher et al. [13]. A great per-
centage of these, as high as 92.3%, were found in less ag-
gressive GIST: very low, low or intermediate risk. These
findings are closer to data published by Rössle et al. [32],
who did not find any mutations in exons 12 or 18 in the
PDGFR-α gene in a population study for the mutational
spectrum of metastatic GIST in Switzerland. Emile et al.
[33] and Heinrich et al. [34] found less than 3% of patients
with exon 18 PDGFR-α mutation in a population-based
and clinical trial in advanced GIST. By contrast, however,
in another population-based study, Cassier et al. [31]
found this type of mutation to be more frequent than we
did in high-risk GIST.Table 7 Multivariate analysis of risk factors for observed
survival
Variable HR p value
Age (>65 vs 0 to 64 years old) 2.22 (1.11 to 4.41) 0.02
Sex (men vs women) 1.78 (0.96 to 3.26) 0.06
Type of mutation
KIT 09 vs KIT 11 1.46 (0.44 to 4.79) 0.53
PDGRF vs KIT 11 1.07 (0.4 to 2.87) 0.90
WT vs KIT 11 1.21 (0.56 to 2.57) 0.63
All other vs KIT 11 0.83 (0.44 to 1.58) 0.58
Fletcher’s risk groups
IR vs LR 1.58 (0.65 to 3.88) 0.32
HR vs LR 2.27 (0.96 to 5.37) 0.06
Met vs LR 11.49 (2.9 to 45.54) <0.001
Site
C17 vs C16 1.08 (0.57 to 2.05) 0.82
All other vs C16 1.23 (0.33 to 4.58) 0.76
Data in italics show significance.
HR, hazard ratio; LR, low risk (includes very low risk); IR, intermediate risk; HR, high
risk; Met, diagnosed in metastatic disease; C16, stomach; C17, small intestine.Moreover, 61.2% of cases with mutation of exon 11 of
the c-KIT gene in our series were diagnosed in a high-
risk group or with metastatic disease, similar to that
published by Cassier et al. [31] in a population-based
study in France.
In contrast to other series, no exon 13 or 17 of the c-
KIT gene mutation was found in our study. Exon 17 mu-
tations account for fewer than 1% of cases in almost all
published series [27,28,31] and mutations of exon 13
were described in 3.7% of cases by Cassier et al. [31],
3.3% by Steiger et al. [27] and no cases were found by
Braconi et al. from 104 samples [28]. As explained previ-
ously, we analyzed BRAF mutation only in wild-type
GIST and did not find any mutated cases, in contrast to
the 13% published by Hostein et al. [10].
Regarding localization of the primary tumor, those
cases with mutation in exon 11 of the c-KIT gene
showed the same distribution as for GIST as a whole,
that is, almost 60% of neoplasm in the stomach and 40%
in the small intestine. What is remarkable in our series
is that all cases with mutations of exon 18 in the
PDGFR-α gene were gastric GIST and 75% of exon 9 c-
KIT mutations were in the small intestine. A predomin-
ance of extra-gastric localization and poor prognosis has
also been described for this type of mutation [35].
Focusing on survival, our data suggests a good survival
for patients with mutation of exon 18 of the PDGFR-α
gene, in accordance with the fact that these patients
were diagnosed with a less aggressive GIST than those
with another type of mutation and predominantly in a
gastric location. Despite this, we did not find differences
between types of mutation in multivariate analysis. This
finding must be taken into account as some trials estab-
lished less sensitivity to imatinib in GIST with D842V
type of mutation in exon 18 PDGFR-α gene [36]. More-
over, some authors had reported lower survival in
PDGFR-α mutated GIST in patients with more advanced
disease than our series [37].
In addition, the 5- and 10-year observed and relative
survival of patients with mutation of exon 11 is slightly,
although not significantly, lower than the cohort as a
whole, reflecting a predominance of high-risk GIST.
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compared with other published studies may mean that
some less aggressive GIST have been missed. We in-
cluded cases diagnosed before the Consensus Workshop
of 2001 [12] and after that the improvement in the
knowledge of GIST could have raised the diagnosis of
those and consequently the incidence [38].
In this population-based analysis, GIST patients have
an increased risk of developing a second cancer and
most of them are diagnosed synchronously. Recently,
Phan et al. [39] published the results of SEER (Surveil-
lance Epidemiology and End Results program) in which
the rate of second cancer after GIST was 7.07%. The SIR
between observed and expected second neoplasm was
2.03 (CI 0.34 to 2.05) in the pre-imatinib era (1992 to
2001) and 1.27 (CI 0.96 to 1.66) in the imatinib era
(2002 to 2009), with an increased risk for colon adeno-
carcinoma and renal cell carcinoma after GIST in the
imatinib era.
It was not possible in our series to perform a statistical
analysis of the risk of developing another cancer follow-
ing GIST by pairs of each second neoplasm, due to the
small number of cases, although we found a higher per-
centage of second tumors than SEER study, reflecting
maybe a more exhaustive case-finding procedure. The
study of the existence of shared etiologic factors between
GIST and other neoplasm deserves further investigation.
Conclusions
Our population-based study shows a mutation-type distri-
bution in the c-KIT and PDGFR-α genes in GIST patients
similar to that found in other population-based studies and
a survival of the most frequent mutation, exon 11 c-KIT
gene, similar to that of the GIST group as a whole.
GIST with an exon 18 PDGFR-α mutation are, in our
population-based analysis, less aggressive and display
better survival, although they may be difficult to treat
with systemic therapies at recurrence.
In our population-based study, GIST patients have an
increased risk of developing a second neoplasm.
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